Skip to content
OpenCapital
Get started

Repligen RGEN Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale

Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×—
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's proceeds from maturities, prepayments and calls of debt securities, available-for-sale.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
Repligen (RGEN) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $66M in Q1 2026.
What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
This measures cash inflows resulting from the natural maturity or early redemption of debt securities held in the investment portfolio. It indicates the recurring cash generation from the company's fixed-income investment strategy.